#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Semaglutide and pancreatic cancer risk
A 2026 meta-analysis of randomised trials found no increased pancreatic cancer risk with semaglutide, consistent with two earlier reviews of the GLP-1 class.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Semaglutide vs dulaglutide in UK practice
A UK cohort study of 6,616 adults found semaglutide lowered HbA1c by 0.22 points more than dulaglutide over one year, with 1.92 kg more weight loss.
Boerhaave syndrome after semaglutide use
A 2026 case report describes the first documented esophageal perforation linked to GLP-1 agonist-induced vomiting after skipping dose titration.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.
Oral Wegovy tracker: FDA, EMA, MHRA
The FDA, EMA, and MHRA have now all approved oral Wegovy for weight management. Here is the regulatory timeline and how the three decisions compare.
Radiolabeling peptides in fewer steps
A 2026 study reports a hydroformylation method that installs carbon-14 or tritium labels on peptides, including semaglutide analogs.
Stopping semaglutide before abdominoplasty
A retrospective study of 80 patients finds that stopping semaglutide four weeks before abdominoplasty normalised complication rates.
Peptide Stacks With Tirzepatide
No clinical trial has studied BPC-157, TB-500, or CJC-1295 in combination with tirzepatide. Here is what the evidence shows.